» Authors » Juan-Carlos Lopez-Talavera

Juan-Carlos Lopez-Talavera

Explore the profile of Juan-Carlos Lopez-Talavera including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 64
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Hruska M, Chan P, Ahmad A, Freeman J, Horga M, et al.
J Clin Pharmacol . 2014 Jul; 55(1):63-72. PMID: 25043197
Peginterferon lambda-1a (Lambda) is under clinical development for the treatment of chronic hepatitis B and C virus (HBV, HCV, respectively) infection. This is the first of two manuscripts detailing the...
2.
Hruska M, Wang X, Chan P, Ahmad A, Freeman J, Horga M, et al.
J Clin Pharmacol . 2014 Jul; 55(1):73-80. PMID: 25042797
This is the second of two manuscripts detailing the pharmacodynamic derivation of peginterferon lambda-1a (Lambda) dosing and treatment durations for Phase 3 studies in hepatitis C virus (HCV) infection, based...
3.
Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, et al.
Antimicrob Agents Chemother . 2012 Feb; 56(4):1838-44. PMID: 22290978
Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032),...
4.
Garcia-Ocana A, Takane K, Reddy V, Lopez-Talavera J, Vasavada R, Stewart A
J Biol Chem . 2002 Oct; 278(1):343-51. PMID: 12403787
Hepatocyte growth factor (HGF) increases beta cell proliferation and function in rat insulin promoter (RIP)-targeted transgenic mice. RIP-HGF mouse islets also function superiorly to normal islets in a transplant setting....